Introduction Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring alopecia. AA prevalence varies between 0.02% and 0.21% (1), with adults being more commonly affected than ...

Rezpegaldesleukin progresses in the pipeline as a treatment for severe-to-very severe alopecia areata.

On July 30, 2025, AbbVie announced positive and top-line data from the phase 3 Up-AA clinical program (NCT06012240), in which upadacitinib (Rinvoq) 15 mg and 30 mg demonstrated that 44.6% and 54.3% of ...

Those who get their hair back after an episode of alopecia probably didn’t have moderate to severe hair loss. Learn about other contributing factors.